Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab
| Autor: | Francesco Passiglia, Michele Aieta, Marco Imperatori, Giovanni Mansueto, Marco Russano, Alfredo Berruti, Giulia Pasquini, Daniele Santini, Elisa Roca, Tindara Franchina, Lorenzo Calvetti, Antonio Galvano, Anna Maria Di Giacomo, Iacopo Fioroni, Giuseppe Aprile, Daniela Iacono, Alessio Cortellini, Sandro Barni, Olga Martelli, Luana Calabrò, Michele Maio, Alain Gelibter, Maria Rita Migliorino, Bruno Vincenzi, Alessandro Russo, Corrado Ficorella, Olga Venditti, Silvia Quadrini, Salvatore Intagliata, Enrico Vasile, Giuseppe Tonini, Fausto Petrelli, Vincenzo Adamo, Alfredo Falcone, Mario Occhipinti, Antonio Russo, Andrea Napolitano, Francesco Pantano |
|---|---|
| Přispěvatelé: | Pantano F., Russano M., Berruti A., Mansueto G., Migliorino M.R., Adamo V., Aprile G., Gelibter A., Ficorella C., Falcone A., Russo A., Aieta M., Maio M., Martelli O., Barni S., Napolitano A., Roca E., Quadrini S., Iacono D., Calvetti L., Occhipinti M.A., Cortellini A., Vasile E., Passiglia F., Imperatori M., Calabro L., Di Giacomo A.M., Petrelli F., Pasquini G., Franchina T., Venditti O., Intagliata S., Galvano A., Fioroni I., Vincenzi B., Tonini G., Santini D. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Adult Male medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Clinical Biochemistry Kaplan-Meier Estimate Disease-Free Survival Drug Administration Schedule NO 03 medical and health sciences 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung Drug Discovery medicine Malignant pleural effusion Humans immunotherapy malignant pleural effusion nivolumab non-small-cell lung cancer In patient Lung cancer Immune Checkpoint Inhibitors Retrospective Studies Pharmacology business.industry Brain Neoplasms Liver Neoplasms Immunotherapy medicine.disease Prognosis Pleural Effusion Malignant respiratory tract diseases 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Female sense organs Non small cell Nivolumab business |
| Popis: | Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|